Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;8(8):26-33.

A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia

Srihari Gopal  1 , Gahan Pandina, Rosanne Lane, Isaac Nuamah, Bart Remmerie, Danielle Coppola, David Hough
Affiliations

A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia

Srihari Gopal et al. Innov Clin Neurosci. 2011 Aug.

Abstract

Objective: First-month data of a 13-week acute schizophrenia study were used to compare paliperidone palmitate to oral risperidone during initiation of long-acting injectable risperidone.

Design: Double-blind, randomized study.

Setting: Outpatient or inpatient.

Participants: Adults with established (≥1 year) schizophrenia. Those assigned to risperidone long-acting injectable (n=460) received 25mg on Days 8 and 22 with oral risperidone (l-6mg) supplementation for the first 28 days. The paliperidone palmitate group (n=453) received 150mg eq. on Day 1, l00mg eq. on Day 8, and oral placebo supplementation for the first 28 days.

Measurements: Positive and Negative Syndrome Scale, Personal and Social Performance Scale, Clinical Global Impression-Severity score, and responder rate (percentage of patients with ≥30% reduction in PANSS total score). An analysis of covariance model estimated least-square mean differences between treatment groups. A post-hoc analysis of efficacy data for the period of interest, i.e., at the time points before and after the first 28 days, was conducted.

Results: Positive and Negative Syndrome Scale, Personal and Social Performance Scale, Clinical global Impression-Severity scores showed similar efficacy between the treatment groups during the first weeks of treatment, corresponding to the risperidone long-acting injection initiation period. Mean Positive and Negative Syndrome Scale total score at baseline was 84.7 for paliperidone palmitate and 84.4 for oral risperidone, on Day 22 was 73.6 and 74.1, respectively, and on Day 36 was 71.8 and 72.8, respectively. Overall incidence of adverse events in the first 28 days was generally similar (45% for paliperidone palmitate vs. 35% for oral risperidone), except for injection site pain (4.6% vs. 0.7%). Similar active moiety plasma concentrations were obtained during this period.

Conclusion: During the first month, paliperidone palmitate without oral supplementation has similar efficacy and safety to oral risperidone (during initiation of risperidone long-acting injectable) in acutely exacerbated schizophrenia.

Keywords: Paliperidone palmitate; acute schizophrenia; long-acting injection; risperidone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean (95% confidence interval) Positive and Negative Syndrome Scale total score during the first 36 days of treatment (last observation carried forward): intent-to-treat analysis set
Figure 2
Figure 2
Mean (95% confidence interval) Clinical Global Impression-Severity Score during the first 36 days of treatment (last observation carried forward): intent-to-treat analysis set
Figure 3
Figure 3
Percentage of patients who were classified as Positive and Negative Syndrome Scale responder during the first 36 days of treatment: intent-to-treat analysis set
Figure 4
Figure 4
Plasma concentration of active moiety for the first 36 days
See this image and copyright information in PMC

References

    1. American Psychiatric. Association Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2004;161:l–56.
    1. Dixon L, Perkins D, Calmes C. Guideline Watch (September 2009): Practice Guideline for the treatment of Patients with Schizophrenia. Arlington, VA: American Psychiatric Press Inc.; 2009. pp. 1–10.
    1. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Schizophrenia Patient Outcomes Research Team (PORT) The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103. - PMC - PubMed
    1. Risperdal® Consta® Prescribing Information. [February 1, 2011]. (last updated December 2010) http://janssencns.com/sites/default/files/pdf/risperdal/risperdalconsta.pdf.
    1. Zyprexa® Relprew™ Prescribing Information. [May 16, 2011]. (last updated in December 2010) http://dailymed.nlm.nih.gov/dailym ed/drugInfo.cfm?id=34272&CFID=1744491....

LinkOut - more resources